Compare VanEck Junior Gold Miners (GDXJ) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Junior Gold Miners vs Summit Therapeutics Inc — how do they compare? VanEck Junior Gold Miners trades at $114.43 (market cap $8.22B), while Summit Therapeutics Inc trades at $17.59 (market cap $13.71B). The key difference: Summit Therapeutics Inc is the larger of the two by market cap, and Summit Therapeutics Inc is more actively traded (6,173,057 versus 3,212,198). Which is the better fit depends on your goals — on Pluang, investors hold VanEck Junior Gold Miners for 41 Days and Summit Therapeutics Inc for 16 Days on average.
| GDXJ | SMMT | |
|---|---|---|
Market Cap | $8.22B | $13.71B |
Volume | 3,212,198 | 6,173,057 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $156.19 | $26.38 |
52-Week Low | $87.56 | $12.43 |
Typical Hold Time | 41 Days | 16 Days |
Enterprise Value | — | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GDXJ, the VanEck Junior Gold Miners ETF, trades at $114.43, up 4.85% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The ETF is undergoing significant rebalancing, with multiple junior mining companies like Sinda Ltd. and Hemlo Mining Corp. being added to the fund as of September 2026, which may impact liquidity and composition. Key financial ratios are not applicable as this is an ETF tracking a basket of stocks.
The outlook is mixed; recent gold price strength above $4,400 (24/7 Wall Street, August 16, 2026) supports miner ETFs, but GDXJ's bearish technicals and institutional selling (Amundi reduced its stake by 50.5% as per Defense World, August 6, 2026) suggest caution. Risks include gold price volatility and the high-risk nature of junior miners. Investment appeal hinges on gold's momentum versus the ETF's technical weakness.
Summit Therapeutics (SMMT) trades at $17.59, down 2.01% on the day, amid mixed earnings performance but strong analyst support with a consensus price target of $29.33. The stock shows a bullish technical signal from moving averages, with key support at $17 and resistance at $18. Recent news highlights a major $2 billion strategic investment from AstraZeneca and expanded clinical collaborations, boosting investor optimism despite current negative profitability metrics.
The outlook for SMMT is heavily driven by clinical progress and partnerships, offering significant upside if drug trials succeed, but carries high risk due to substantial losses, negative cash flow from operations, and reliance on positive trial outcomes. Investors should weigh the potential rewards against the company's current financial health and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Junior Gold Miners
GDXJ provides exposure to small and mid-cap companies in the global gold and silver mining industry. It focuses on 'junior' miners involved in exploration and early production, featuring 2026 leaders like Pan American Silver and Coeur Mining.
Read more on GDXJ →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
